Valuation: Celgene

Market Cap 7.7TCr 6.78TCr 6.43TCr 5.8TCr 11TCr 7,38600Cr 11TCr 77TCr 30TCr 3,77600Cr 29TCr 28TCr 12,10600Cr P/E 2017
28.7x
P/E 2018 11.6x
Enterprise Value 9.13TCr 8.04TCr 7.61TCr 6.87TCr 13TCr 8,75000Cr 13TCr 91TCr 35TCr 4,47300Cr 34TCr 34TCr 14,34100Cr EV / Sales 2017
6.61x
EV / Sales 2018 3.86x
Free-Float
-
Yield 2017 *
-
Yield 2018 -
15/23/15 Sutro Biopharma, Inc. Receives a Notice of Termination from Celgene Corporation CI
08/21/08 Biocon Limited, Biocon Pharma Limited and Biocon Pharma Inc. Enters into A Confidential Settlement Agreement with Celgene Corporation CI
22/21/22 Celgene Corporation Will Grant Sun Pharmaceutical Industries Limited A License to Celgene's Patents Required to Manufacture and Sell Certain Limited Quantity CI
23/21/23 Celgene Corporation Issues Notice of Redemption of Notes CI
04/21/04 Bristol-Myers Squibb Company and Celgene Corporation Announce Tender Offers for an Aggregate Purchase Price of Up to $4.0 Billion CI
05/21/05 Ikena Oncology, Inc. announced that it has received $120 million in funding from a group of investors CI
23/20/23 Amgen : Signs Licensing Agreement With Medicines Development for Global Health MT
05/20/05 Bristol Myers Squibb : Q3 Results Beat Estimates; Raises 2020 EPS Outlook MT
23/20/23 Silverback Therapeutics, Inc. announced that it has received $84.999996 million in funding from a group of investors CI
22/20/22 Silverback Therapeutics, Inc. announced that it expects to receive $84.999996 million in funding from a group of investors CI
26/20/26 Agios Pharmaceuticals, Inc. Provides Update on 2016 Collaboration Agreement with Celgene CI
11/20/11 Silverback Therapeutics, Inc. announced that it has received $68.400013 million in funding from a group of investors CI
04/20/04 Pulmonary Fibrosis Foundation Launches Industry Consortium to Identify Biomarkers in Pulmonary Fibrosis CI

Financials

2017 2018
Net sales 1.3TCr 1.15TCr 1.08TCr 979.42Cr 1.85TCr 1,24700Cr 1.87TCr 13TCr 5TCr 64TCr 4.88TCr 4.78TCr 2,04300Cr 1.53TCr 1.35TCr 1.27TCr 1.15TCr 2.17TCr 1,46500Cr 2.2TCr 15TCr 5.87TCr 75TCr 5.74TCr 5.61TCr 2,40100Cr
Net income 294Cr 258.9Cr 245.3Cr 221.45Cr 417.38Cr 28TCr 422.77Cr 2.93TCr 1.13TCr 14TCr 1.1TCr 1.08TCr 46TCr 404.6Cr 356.29Cr 337.57Cr 304.76Cr 574.39Cr 39TCr 581.81Cr 4.04TCr 1.55TCr 20TCr 1.52TCr 1.49TCr 64TCr
Net Debt 379.3Cr 334.01Cr 316.47Cr 285.7Cr 538.47Cr 36TCr 545.43Cr 3.79TCr 1.46TCr 19TCr 1.42TCr 1.39TCr 60TCr 1.42TCr 1.25TCr 1.19TCr 1.07TCr 2.02TCr 1,36400Cr 2.04TCr 14TCr 5.46TCr 70TCr 5.34TCr 5.22TCr 2,23500Cr
Logo Celgene
Celgene Corporation specializes in the design, development, and sale of products for treating cancer and immune system disorders. Net sales break down by product family as follows: - therapeutic products (99.9%); - other (0.1%): cellular therapy products and biological materials for implants, for tissue and organ treatments, and for therapeutic product development. Net sales are distributed geographically as follows: the United States (65.6%), Europe (24.7%) and other (9.7%).
Employees
-
Sector
-
  1. Stock Market
  2. Stocks
  3. CELG Stock